

# Mefloquine

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.3. Antimalarial medicines](#) > [6.5.3.1. Antimalarial medicines](#) > [Medicines for curative treatment](#)

		EMLc	ATC codes: <a href="#">P01BC02</a>
Indication	Malaria due to Plasmodium vivax	ICD11 code: <a href="#">1F81</a>	
INN	Mefloquine		
Medicine type	Chemical agent		
List type	Core (EML) (EMLc)		
Additional notes	To be used in combination with artesunate 50 mg		
Formulations	Oral > Solid: 250 mg tablet (hydrochloride)		
EML status history	First added in 1987 ( <a href="#">TRS 770</a> ) Changed in 1993 ( <a href="#">TRS 850</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 946</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Removed in 2025 ( <a href="#">TRS 1064</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . <a href="#">↗</a>		
Wikipedia	<a href="#">Mefloquine</a> <a href="#">↗</a>		
DrugBank	<a href="#">Mefloquine</a> <a href="#">↗</a>		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - to delete the listing of single agent mefloquine from the EML and EMLc, noting that fixed dose combinations of artesunate + mefloquine are available and preferred for the curative treatment of malaria.

